Related references
Note: Only part of the references are listed.Emerging functions of the EGFR in cancer
Sara Sigismund et al.
MOLECULAR ONCOLOGY (2018)
Epidermal growth factor receptor and ligand family expression and activity in glioblastoma
Caroline von Achenbach et al.
JOURNAL OF NEUROCHEMISTRY (2018)
Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice
He Li et al.
CELL DEATH & DISEASE (2018)
Pharmacological activation of autophagy favors the clearing of intracellular aggregates of misfolded prion protein peptide to prevent neuronal death
Stefano Thellung et al.
CELL DEATH & DISEASE (2018)
Clinical Applications of Autophagy Proteins in Cancer: From Potential Targets to Biomarkers
Svetlana Bortnik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells
Carolina D'Alesio et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Epigenetic Control of Autophagy: Nuclear Events Gain More Attention
Sung Hee Baek et al.
MOLECULAR CELL (2017)
Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells
Paola Bagnato et al.
ONCOTARGET (2017)
Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
Martina Di Modica et al.
DISEASE MARKERS (2017)
CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes
Limin Xia et al.
CANCER CELL (2017)
Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib
Suning Chen et al.
TUMOR BIOLOGY (2016)
The Chromatin Remodeling Complex Chd4/NuRD Controls Striated Muscle Identity and Metabolic Homeostasis
Pablo Gomez-del Arco et al.
CELL METABOLISM (2016)
Mechanisms and functions of lysosome positioning
Jing Pu et al.
JOURNAL OF CELL SCIENCE (2016)
AKT signaling in ERBB2-amplified breast cancer
F. Javier Carmona et al.
PHARMACOLOGY & THERAPEUTICS (2016)
RNAi screens identify CHD4 as an essential gene in breast cancer growth
Carolina D'Alesio et al.
ONCOTARGET (2016)
Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells
Patrizio Castagnola et al.
ONCOTARGET (2016)
Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway
Fu-Zheng Wei et al.
AUTOPHAGY (2015)
Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation
Justin Sperlazza et al.
BLOOD (2015)
Defeating EpCAM+ liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma
Kouki Nio et al.
JOURNAL OF HEPATOLOGY (2015)
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
Pernelle Lavaud et al.
BMC MEDICINE (2014)
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition
Milos Dokmanovic et al.
CANCER BIOLOGY & THERAPY (2014)
The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes
Y. Cai et al.
ONCOGENE (2014)
Lysosome Transport as a Function of Lysosome Diameter
Debjyoti Bandyopadhyay et al.
PLOS ONE (2014)
The Mysterious Ways of ErbB2/HER2 Trafficking
Vibeke Bertelsen et al.
MEMBRANES (2014)
CHD4 in the DNA-damage response and cell cycle progression: not so NuRDy now
Aoife O'Shaughnessy et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
Transient Activation of Autophagy via Sox2-Mediated Suppression of mTOR Is an Important Early Step in Reprogramming to Pluripotency
Shuo Wang et al.
CELL STEM CELL (2013)
The Therapeutic Target Hsp90 and Cancer Hallmarks
Yoshihiko Miyata et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Trastuzumab: updatedmechanisms of action and resistance in breast cancer
Thuy Vu et al.
FRONTIERS IN ONCOLOGY (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
Ravi K. Amaravadi et al.
CLINICAL CANCER RESEARCH (2011)
Heterogeneity in breast cancer
Kornelia Polyak
JOURNAL OF CLINICAL INVESTIGATION (2011)
Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis
Cristina Rodriguez-Antona et al.
ENDOCRINE-RELATED CANCER (2010)
Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
Alejandro Vazquez-Martin et al.
PLOS ONE (2009)
TGFα expression impairs trastuzumab-induced HER2 downregulation
G Valabrega et al.
ONCOGENE (2005)
HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27(Kip1) via multiple signaling pathways
XF Le et al.
CELL CYCLE (2005)
A new mathematical model for relative quantification in real-time RT-PCR
MW Pfaffl
NUCLEIC ACIDS RESEARCH (2001)
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
D Harari et al.
ONCOGENE (2000)
Share Paper
